Premium
Tolterodine: As effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder
Author(s) -
Lee Jeong Gu,
Hong Jae Yup,
Choo MyungSoo,
Kwon Hun Young,
Chung Do Young,
Lee Kyu Sung,
Lee Ji Youl,
Lee Tack
Publication year - 2002
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1046/j.1442-2042.2002.00460.x
Subject(s) - tolterodine , oxybutynin , overactive bladder , tolerability , medicine , urology , adverse effect , alternative medicine , pathology
Background:This double‐blind, multicenter study compared the efficacy and tolerability of tolterodine (Pharmacia, Los Angeles, USA) with that of oxybutynin (Alza, Palo Alto, USA) in Asian patients with overactive bladder.Methods:Two‐hundred‐and‐twenty‐eight adults with overactive bladder symptoms were randomized to receive tolterodine 2 mg twice daily (bid) ( n = 112) or oxybutynin 5 mg bid ( n = 116). After 8 weeks’ treatment, changes in micturition diary variables, patients’ perception of treatment benefit, and tolerability endpoints were determined.Results:The mean (± SD) number of micturitions/24 h decreased by 2.6 ± 2.9 (−21%) with tolterodine and 1.8 ± 4.2 (−15%) with oxybutynin (both P = 0.0001 vs baseline). The mean number of incontinence episodes/24 h decreased by 2.2 ± 2.3 (−85%) in the tolterodine group and by 1.4 ± 1.8 (−58%) in the oxybutynin group (both P = 0.0001 vs baseline). Patient perception of treatment benefit was over 70% in each treatment group. Adverse events were significantly lower in the tolterodine group compared with oxybutynin‐treated patients (55% vs 82%; P = 0.001). Dry mouth was reported by significantly fewer patients on tolterodine, compared with oxybutynin (35% vs 63%; P = 0.001) and withdrawals due to adverse events were lower in the tolterodine group than with those treated with oxybutynin (10% vs 16%). There were no safety concerns.Conclusions:Tolterodine 2 mg bid is equally or more effective than oxybutynin 5 mg bid in the treatment of Asian patients with overactive bladder, and shows significantly better tolerability. This may enhance compliance during long‐term treatment.